Emerging Technologies (15)

Molly Gibson, president of future science at Lila Sciences, discusses the company's superintelligence platform to advance scientific research, AI technology's promise in curing diseases and the risks the company is watching out for.

Morgan Cheatham, partner and head of healthcare and life sciences at Breyer Capital, highlights the venture capital firm's strategy for funding emerging technologies and its rigorous evaluation of a technology's potential for maturation.

Precision Neuroscience kicks off the Emerging Technologies series, with Jayme Strauss, the company’s chief clinical and commercial officer, discussing the Layer 7 cortical interface, a minimally invasive brain-computer interface.